Long
$AZN Covid wave 2 play ($MRNA $GILD $INO $SPY)
see full chart at tradingview.com/u/WallSt007
AZN
Entry $51.68
Target $53
stoploss $50
Why this play?
they are really trying to push the Covid wave 2 case, and the market is crash. so if wave 2 really comes, these stocks should pump even further.
What is AZN?
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology,
cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.
The company serves primary care and specialty care physicians through distributors and local representative offices.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AZN
Entry $51.68
Target $53
stoploss $50
Why this play?
they are really trying to push the Covid wave 2 case, and the market is crash. so if wave 2 really comes, these stocks should pump even further.
What is AZN?
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology,
cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.
The company serves primary care and specialty care physicians through distributors and local representative offices.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
Trade closed: target reached
closed at $53 a while back, will be looking for re-entry soonNote
updated chart
If you appreciate my technical analysis and want to check out our
Free Newsletter --> diywallst.com/
Free Newsletter --> diywallst.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
If you appreciate my technical analysis and want to check out our
Free Newsletter --> diywallst.com/
Free Newsletter --> diywallst.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.